Once-nightly oral pill helps control obstructive sleep apnea

https://www.news-medical.net/news/20260518/Once-nightly-oral-pill-helps-control-obstructive-sleep-apnea.aspx A once-nightly oral pill helped control obstructive sleep apnea in a large, phase 3 clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to treat OSA by addressing its underlying mechanisms and targeting the neuromuscular causes of airway collapse. "Aroxybutynin and Atomoxetine (AD109) for Obstructive Sleep Apnea: A Randomized Phase 3 Trial" will be published in the American Journal of Respiratory and Critical Care Medicine.